

August 11, 2021

The Secretary Listing Department, BSE Limited, 1 st Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai 400001 Scrip Code: 540975	The Manager, Listing Department, The National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G Bandra Kurla Complex Bandra (East), Mumbai 400051 Scrip Symbol: ASTERDM
---	--

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on August 11, 2021

Ref: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject, we wish to inform you that:

1. The Meeting of the Board of Directors commenced at 04.30 pm (IST) and concluded at 8.15 pm (IST).
2. The unaudited financial results (standalone and consolidated) of the Company for the quarter ended June 30, 2021 together with the Limited Review Report has been reviewed by the Audit Committee and considered and approved by the Board of Directors, has been enclosed herewith as **Annexure-1**.
3. Publication of the results in the Newspaper is being done as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kindly take the above said information on record as per the requirement of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thank You.

For **Aster DM Healthcare Limited**



Puja Aggarwal
Company Secretary and Compliance Officer

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF ASTER DM HEALTHCARE LIMITED

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Aster DM Healthcare Limited ("the Company"), for the quarter ended 30 June 2021 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted, as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. Emphasis of Matter

We draw attention to Note 6 of the Statement, which describes the effects of the continuing uncertainties arising from the outbreak of COVID-19 pandemic and the consequential impact on the financial results of the Company for the quarter ended 30 June 2021.


Our conclusion on the Statement is not modified in respect of this matter.

6. The comparative financial information of the Company for the quarter ended 30 June 2020 prepared in accordance with Ind AS included in this Statement have been reviewed by the predecessor auditor. The report of the predecessor auditor on this comparative financial information dated 12 August 2020 expressed an unmodified conclusion.

Our conclusion on the Statement is not modified in respect of this matter.

For **DELOITTE HASKINS & SELLS**
Chartered Accountants
(Firm's Registration No. 008072S)

JAIDEEP
SATISHCHANDR
A TRASI

 Digitally signed by JAIDEEP
SATISHCHANDRA TRASI
Date: 2021.08.11 19:41:34
+05'30'

Jaideep S. Trasi
(Partner)
(Membership No. 211095)
(UDIN: 21211095AAAACO1636)

Bengaluru, 11 August 2021

Aster DM Healthcare Limited

CIN : L85110KA2008PLC147259

Registered office : No.1785, Sarjapur Road, Sector -1, HSR Layout, Ward No.174, Agara Extension, Bangalore-560102, Karnataka, India

Statement of unaudited standalone financial results for the quarter ended 30 June 2021

(Amount in INR crores)

Particulars	Quarter ended			Year ended
	30 June 2021 (Unaudited)	31 March 2021 (refer Note 13)	30 June 2020 (Unaudited)	31 March 2021 (Audited)
1 Income				
Revenue from operations	252.12	234.43	130.61	746.54
Other income	7.40	6.39	4.79	21.63
Total income	259.52	240.82	135.40	768.17
2 Expenses				
Purchase of medicines and consumables(refer Note 11)	80.68	50.45	34.10	181.66
Changes in inventories	(9.01)	2.53	0.04	4.22
Professional fees to consultant doctors	55.94	54.84	33.80	177.18
Laboratory Outsourcing Charges (refer Note 11)	9.85	17.24	2.15	28.54
Employee benefits expenses	43.38	37.45	33.00	143.78
Finance costs	10.50	8.90	8.44	36.50
Depreciation and amortisation expenses	24.65	22.01	24.70	95.00
Other expenses (refer Note 11)	50.95	60.90	26.68	169.33
Total expenses	266.94	254.32	162.91	836.21
3 Loss before tax (1-2)	(7.42)	(13.50)	(27.51)	(68.04)
4 Tax expense				
Current tax	-	-	-	-
Deferred tax	-	0.74	0.01	0.74
Total tax expense	-	0.74	0.01	0.74
5 Loss for the period / year (3-4)	(7.42)	(14.24)	(27.52)	(68.78)
6 Other comprehensive income / (loss) for the period / year				
<i>Items that will not be reclassified subsequently to profit or loss</i>				
Remeasurement of net defined benefit liability	-	0.01	(0.04)	0.01
Income tax relating to items that will not be reclassified to profit or loss	-	-	0.01	-
Other comprehensive income / (loss), net of taxes	-	0.01	(0.03)	0.01
7 Total comprehensive loss (5+6)	(7.42)	(14.23)	(27.55)	(68.77)
8 Paid-up equity share capital (Face value of INR 10 each)	497.11	497.04	496.80	497.04
9 Other equity				2,367.07
10 Earnings per share (Face value of INR 10 each)				
Basic (in INR)	Not annualised (0.15)	Not annualised (0.29)	Not annualised (0.55)	Annualised (1.38)
Diluted (in INR)	(0.15)	(0.29)	(0.55)	(1.38)

See accompanying notes to the statement of unaudited standalone financial results

Aster DM Healthcare Limited
CIN : L85110KA2008PLC147259

Registered office : No.1785, Sarjapur Road, Sector -1, HSR Layout, Ward No.174, Agara Extension, Bangalore-560102, Karnataka, India

Notes to the statement of unaudited standalone financial results :

- 1) The Statement of unaudited standalone financial results ('the Statement') of Aster DM Healthcare Limited ('the Company') for the quarter ended 30 June 2021 has been reviewed by the Audit Committee and approved by the Board of Directors on 11 August 2021. The Statement has been subjected to a limited review by Deloitte Haskins & Sells, the statutory auditor of the Company. The report of the statutory auditor is unmodified.
- 2) The Statement has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 3) In accordance with Ind AS 108, Operating Segments, segment information has been provided in the statement of unaudited consolidated financial results of the Company and therefore no separate disclosure on segment information is given in the statement of unaudited standalone financial results.
- 4) During the quarter ended 30 June 2021, the Nomination and Remuneration Committee of the Company approved the grant of 95,000 options (exercise price ranging from INR 10 to INR 118) to the employees of the Company and its subsidiaries under the Aster DM Healthcare Limited Employees Stock Option Plan 2013.
- 5) During the quarter ended 30 June 2021, the Company has entered into share purchase agreement with Hindustan Drug House, a partnership firm registered under the Partnership Act, 1932. Hindustan Drug House is in the process of converting into a private limited company. The Company shall invest in 86% of the paid-up equity share capital of the converted private limited company.
- 6) In March 2020, the World Health Organisation declared COVID-19 to be a pandemic. This pandemic resulted in disruption to regular business operations due to lockdown, disruptions in transportation, travel bans, quarantines, social distancing and other emergency measures imposed by the government. The Company adopted measures to curb the spread of infection in order to protect the health of its employees and ensure business continuity with minimal disruption and has considered available internal and external information upto the date of approval of the financial results by the Board of Directors. The Company has used the principles of prudence in applying judgements, estimates and assumptions including sensitivity analysis and the Company has evaluated impact of the pandemic in assessing the recoverability of property plant and equipment (including Capital work in progress), investments, intangibles, inventories, receivables and other assets based on its review of current indicators of future economic conditions. Based on current estimates, including the availability of financing facilities for maintaining liquidity, the Company expects to fully recover the carrying amount of these assets. Further, the Company has taken various measures to reduce its fixed cost - for example, salary reductions, optimization of administrative, sales and marketing costs, deferral of capex along with judicious resource allocation and requesting for the waiver of minimum guarantee fee and revenue share for hospital premises taken on lease. The eventual outcome of impact of the global health pandemic may be different from that which has been estimated as on the date of approval of these financial results. The Company will continue to monitor any material changes to future economic conditions and the consequent impact on its business, if any, and any significant impact of these changes would be recognized in the financial results as and when these material changes to economic conditions arise.
- 7) The Indian Parliament has approved the Code on Social Security, 2020 and Code on Wages, 2019 ['Codes'] relating to employee benefits during employment and post-employment benefits in September 2020 and the same has received Presidential Assent. The Codes have been published in the Gazette of India. However, the date on which the Codes will come into effect has not yet been notified. The Company will need to assess the impact of the above. The impact will be recorded in the first period after the Codes become effective.
- 8) The financial results of the Company for the quarter ended 30 June 2020, were reviewed by B S R & Associates LLP, Chartered Accountants, the predecessor auditor who have expressed an unmodified review conclusion.
- 9) Statement of unaudited standalone financial results are available for perusal at the website of the Company and the stock exchanges.
- 10) The Company has adjusted the value of shares held by the ESOP Trust but not yet allotted to employees of INR 2.72 crores as at 31 March 2020 with the value of the issued, subscribed and paid up capital as at that date, which was previously included under other equity. Accordingly the previously reported financial results for the quarter ended 30 June 2020 have been restated as follows:

(Amount INR crores)

Particulars	As at 30 June 2020	As at 30 June 2020
	(as previously stated)	(as restated)
Equity Share capital	499.52	496.80

The above reclassification does not impact the total value of shareholders' equity

- 11) During the quarter ended 31 March 2021, the Company reclassified certain other consumables from purchase of medicines and consumables to other expenses and has disclosed laboratory outsourcing charges as a separate item of expenditure previously included in other expenses. Comparative numbers for the quarter ended 30 June 2020 have been reclassified accordingly.

(Amount INR crores)

Particulars	Quarter ended 30 June 2020	
	(as previously)	(as restated)
Purchase of medicines and consumables	35.66	34.10
Other Expenses	27.27	26.68
Laboratory Outsourcing Charges	-	2.15
Total expenses	62.93	62.93

- 12) During the quarter ended 31 March 2021 the Company has incurred net loss on fair valuation of put option liability amounting to INR 14.55 crores which is included under other expenses.
- 13) The figures for the quarter ended 31 March 2021 are balancing figures between audited figures in respect of full financial years ended 31 March 2021 and the unaudited published year to date figures upto 31 December 2020, being the end of the third quarter of the respective financial year, which was subjected to Limited Review by the Statutory Auditors.

for and on behalf of the Board of Directors of

Aster DM Healthcare Limited
CIN : L85110KA2008PLC147259

MANDAYAP Digitally signed by
URATH AZAD MANDAYAPURATH
MOOPEN AZAD MOOPEN
Date: 2021.08.11
19:37:37 +05'30'

Dr. Azad Moopen
Chairman and Managing Director
DIN 00159403
Dubai
11 August 2021

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF ASTER DM HEALTHCARE LIMITED

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Aster DM Healthcare Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit after tax and total comprehensive income of its associates for the quarter ended 30 June 2021 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
5. The Statement includes the results of the entities as provided in Annexure 1.
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 8 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. **Emphasis of Matter**

We draw attention to Note 5 of the Statement, which describes the effects of the continuing uncertainties arising from the outbreak of COVID-19 pandemic and the consequential impact on the financial results of the Company for the quarter ended 30 June 2021.

Our conclusion on the Statement is not modified in respect of this matter.

8. We did not review the interim financial information of 56 subsidiaries included in the unaudited consolidated financial results, whose interim financial information reflect total revenues of Rs. 1,824.51 crores for the quarter ended 30 June 2021, total net profit after tax of Rs. 49.64 crores for the quarter ended 30 June 2021 and total comprehensive income Rs. 49.64 crores for the quarter ended 30 June 2021 as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and associates, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of these matters.

9. The unaudited consolidated financial results includes the interim financial information of 15 subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect total revenue of Rs. 49.16 crores for the quarter ended 30 June 2021, total profit after tax of Rs. 0.13 crores for the quarter ended 30 June 2021 and total comprehensive income of Rs. 0.13 crores for the quarter ended 30 June 2021, as considered in the Statement. The unaudited consolidated financial results also includes the Group's share of profit after tax of Rs. 1.04 crores for the quarter ended 30 June 2021 and total comprehensive income of Rs. 1.04 crores for the quarter ended 30 June 2021, as considered in the Statement, in respect of 7 associates whose interim financial information have not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

10. The comparative financial information of the Company for the quarter ended 30 June 2020 prepared in accordance with Ind AS included in this Statement have been reviewed by the predecessor auditor. The report of the predecessor auditor on this comparative financial information dated 12 August 2020 expressed an unmodified conclusion.

Our conclusion on the Statement is not modified in respect of this matter.

For **DELOITTE HASKINS & SELLS**
Chartered Accountants
(Firm's Registration No. 008072S)

JAIDEEP
SATISHCHANDR
A TRASI

Digitally signed by JAIDEEP
SATISHCHANDRA TRASI
Date: 2021.08.11 19:42:49
+05'30'

Jaideep S. Trasi
Partner
(Membership No. 211095)
(UDIN: 21211095AAAACP3637)

Bengaluru, 11 August 2021

Annexure – 1 to the Independent Auditor’s Review Report

S. No	Entity	Relationship	Country of incorporation
1	Aster DM Healthcare Limited	Parent	India
2	DM Med City Hospitals (India) Private Limited	Subsidiary	India
3	Ambady Infrastructure Private Limited	Subsidiary	India
4	Aster DM Healthcare (Trivandrum) Private Limited	Subsidiary	India
5	Malabar Institute of Medical Sciences Limited	Subsidiary	India
6	Prerana Hospital Limited	Subsidiary	India
7	Sri Sainatha Multispeciality Hospitals Private Limited	Subsidiary	India
8	Dr. Ramesh Cardiac and Multispeciality Hospitals Private Limited	Subsidiary	India
9	Aster Clinical Lab LLP	Subsidiary	India
10	Mindriot Research and Innovation Foundation	Subsidiary	India
11	Affinity Holdings Private Limited	Subsidiary	Mauritius
12	EMED Human Resources India Private Limited	Step down Subsidiary	India
13	Ezhimala Infrastructure LLP	Step down Subsidiary	India
14	Warseps Healthcare LLP	Step down Subsidiary	India
15	Sanghamitra Hospitals Private Limited	Step down Subsidiary	India
16	Aster Ramesh Duhita LLP	Step down Subsidiary	India
17	Komali Fertility Centre LLP (earlier Ramesh Fertility Centre LLP)	Step down Subsidiary	India
18	Aster Caribbean Holdings Limited	Step down Subsidiary	Cayman Island
19	Aster Cayman Hospital Limited	Step down Subsidiary	Cayman Island
20	Aster DM Healthcare FZC	Step down Subsidiary	UAE
21	Aster Hospital Sonapur L.L.C	Step down Subsidiary	UAE
22	Radiant Healthcare L.L.C	Step down Subsidiary	UAE
23	Aster Day Surgery Centre LLC	Step down Subsidiary	UAE
24	DM Healthcare (L L C)	Step down Subsidiary	UAE
25	Wahat Al Aman Home Health Care L.L.C.	Step down Subsidiary	UAE
26	Aster Grace Nursing and Physiotherapy LLC	Step down Subsidiary	UAE
27	Aster Pharmacies Group LLC	Step down Subsidiary	UAE
28	New Aster Pharmacy DMCC	Step down Subsidiary	UAE
29	Medshop Garden Pharmacy LLC	Step down Subsidiary	UAE
30	Aster DCC Pharmacy LLC	Step down Subsidiary	UAE
31	Aster Al Shafar Pharmacies Group LLC	Step down Subsidiary	UAE
32	Rafa Pharmacy LLC	Step down Subsidiary	UAE
33	Aster Pharmacy LLC, AUH	Step down Subsidiary	UAE
34	Med Shop Drugs Store LLC	Step down Subsidiary	UAE
35	Alfa Drug Store LLC	Step down Subsidiary	UAE
36	Alfa One Drug Store LLC	Step down Subsidiary	UAE
37	Alfaone FZ-LLC	Step down Subsidiary	UAE
38	DM Pharmacies LLC	Step down Subsidiary	UAE
39	Aster Opticals LLC	Step down Subsidiary	UAE
40	Medcare Hospital (L.L.C)	Step down Subsidiary	UAE
41	Premium Healthcare Limited	Step down Subsidiary	UAE
42	Dr. Moopens Healthcare Management Services LLC	Step down Subsidiary	UAE
43	Eurohealth Systems FZ LLC	Step down Subsidiary	UAE
44	Al Rafa Investments Limited	Step down Subsidiary	UAE

Deloitte Haskins & Sells

S. No	Entity	Relationship	Country of incorporation
45	Al Rafa Holdings Limited	Step down Subsidiary	UAE
46	Alfa Investments Limited	Step down Subsidiary	UAE
47	Active Holdings Limited	Step down Subsidiary	UAE
48	Al Rafa Medical Centre LLC	Step down Subsidiary	UAE
49	Dar Al Shifa Medical Centre LLC	Step down Subsidiary	UAE
50	Aster Primary Care LLC	Step down Subsidiary	UAE
51	Modern Dar Al Shifa Pharmacy LLC	Step down Subsidiary	UAE
52	Harley Street LLC	Step down Subsidiary	UAE
53	Harley Street Pharmacy LLC	Step down Subsidiary	UAE
54	Harley Street Medical Centre LLC	Step down Subsidiary	UAE
55	Harley Street Dental LLC	Step down Subsidiary	UAE
56	Grand Optics LLC	Step down Subsidiary	UAE
57	Noor Al Shefa Clinic LLC	Step down Subsidiary	UAE
58	Zahrath Al Shefa Medical Center L.L.C	Step down Subsidiary	UAE
59	Zahrath Al Shefa Pharmacy LLC	Step down Subsidiary	UAE
60	Samary Pharmacy LLC	Step down Subsidiary	UAE
61	Metro Meds Pharmacy L.L.C	Step down Subsidiary	UAE
62	Metro Medical Center L.L.C	Step down Subsidiary	UAE
63	Symphony Healthcare Management Services LLC	Step down Subsidiary	UAE
64	E-Care International Medical Billing Services Co. LLC	Step down Subsidiary	UAE
65	Al Raffah Hospital LLC	Step down Subsidiary	Oman
66	Al Raffah Pharmacies Group LLC	Step down Subsidiary	Oman
67	Oman Al Khair Hospital L.L.C	Step down Subsidiary	Oman
68	Dr. Moopen's Healthcare Management Services WLL	Step down Subsidiary	Qatar
69	Welcare Polyclinic W.L.L	Step down Subsidiary	Qatar
70	Dr. Moopens Aster Hospital WLL	Step down Subsidiary	Qatar
71	Sanad Al Rahma for Medical Care LLC	Step down Subsidiary	Kingdom of Saudi Arabia
72	Aster DM Healthcare WLL (earlier Aster DM Healthcare SPC)	Step down Subsidiary	Bahrain
73	Orange Pharmacies LLC	Step down Subsidiary	Jordan
74	Al Shafar Pharmacy LLC, AUH	Step down Subsidiary	UAE
75	Aster DM Healthcare INC	Step down Subsidiary	Philippines
76	Aster Medical Centre LLC	Step down Subsidiary	UAE
77	Aster Kuwait Pharmaceuticals and Medical Equipment Company W.L.L	Step down Subsidiary	Kuwait
78	MIMS Infrastructure and Properties Private Limited	Associates	India
79	Alfaone Medicals Private Limited	Associates	India
80	Alfaone Retail Pharmacies Private Limited	Associates	India
81	Aries Holdings FZC	Associates	UAE
82	AAQ Healthcare Investments LLC	Associates	UAE
83	Aries Investments LLC	Associates	UAE
84	Al Mutamaizah Medcare Healthcare Investment Co. LLC	Associates	UAE

Aster DM Healthcare Limited

CIN : L85110KA2008PLC147259

Registered office : No.1785, Sarjapur Road, Sector -1, HSR Layout, Ward No.174, Agara Extension, Bangalore-560102, Karnataka, India

Statement of unaudited consolidated financial results for the quarter ended 30 June 2021

(Amount in INR crores)

Particulars	Quarter ended			Year ended
	30 June 2021	31 March 2021	30 June 2020	31 March 2021
	(Unaudited)	(refer note 11)	(Unaudited)	(Audited)
1 Income				
Revenue from operations (refer Note 7)	2,371.59	2,390.88	1,747.17	8,608.43
Other income	8.04	29.81	6.52	49.97
Total income	2,379.63	2,420.69	1,753.69	8,658.40
2 Expenses				
Purchase of medicines and consumables (refer Note 7 & 9)	804.99	595.48	631.66	2,436.95
Changes in inventories	(90.90)	69.64	(62.45)	111.96
Professional fees to consultant doctors	187.72	177.48	118.62	643.42
Laboratory outsourcing charges (refer Note 9)	73.11	140.17	19.02	275.90
Employee benefits expenses	757.08	702.50	624.50	2,755.36
Finance costs	66.46	76.73	80.28	293.66
Depreciation and amortisation expenses	152.98	152.64	154.71	617.57
Other expenses (refer Note 9)	358.74	384.53	273.09	1,322.05
Total expenses	2,310.18	2,299.17	1,839.43	8,456.87
3 Profit/ (loss) before exceptional item (1-2)	69.45	121.52	(85.74)	201.53
4 Exceptional items	-	-	-	-
5 Profit/ (loss) before share of profit of equity accounted investees and tax (3+4)	69.45	121.52	(85.74)	201.53
6 Share of profit of equity accounted investees	1.04	0.45	1.02	3.52
7 Profit/ (loss) before tax (5+6)	70.49	121.97	(84.72)	205.05
8 Tax expense				
Current tax	11.37	5.67	3.37	21.66
Current tax for earlier years	-	(1.59)	1.37	-
Deferred tax	(0.48)	1.17	(0.87)	5.56
Total tax expense	10.89	5.25	3.87	27.22
9 Profit/ (loss) for the period/ year (7-8)	59.60	116.72	(88.59)	177.83
10 Other comprehensive income/ (loss) for the period/ year				
<i>Items that will not be reclassified subsequently to profit or loss</i>				
Remeasurement of net defined benefit liability	-	(13.10)	0.07	(13.10)
Income tax on items that will not be reclassified subsequently to profit or loss	-	0.04	(0.01)	0.04
<i>Items that will be reclassified subsequently to profit or loss</i>				
Exchange difference in translating financial statements of foreign operations	28.25	5.62	11.74	(36.65)
Income tax on items that will be reclassified subsequently to profit or loss	(8.81)	-	-	-
Other comprehensive income/ (loss), net of taxes	19.44	(7.44)	11.80	(49.71)
11 Total comprehensive income/ (loss) (9+10)	79.04	109.28	(76.79)	128.12
12 Profit/ (loss) attributable to :				
Owners of the Company	44.47	105.39	(82.93)	147.74
Non-controlling interests	15.13	11.33	(5.66)	30.09
Profit/ (loss) for the period/ year	59.60	116.72	(88.59)	177.83
13 Other comprehensive income/ (loss) attributable to :				
Owners of the Company	16.47	(1.52)	10.50	(43.79)
Non-controlling interests	2.97	(5.92)	1.30	(5.92)
Other comprehensive income/ (loss) for the period/ year	19.44	(7.44)	11.80	(49.71)
14 Total comprehensive income/ (loss) attributable to :				
Owners of the Company	60.94	103.87	(72.43)	103.95
Non-controlling interests	18.10	5.41	(4.36)	24.17
Total comprehensive income/ (loss) for the period/ year (12+13)	79.04	109.28	(76.79)	128.12
15 Paid-up equity share capital (Face value of INR 10 each)	497.11	497.04	496.80	497.04
16 Other equity	-	-	-	2,875.42
17 Earnings per share (Face value of INR 10 each)				
Basic (in INR)	Not annualised	Not annualised	Not annualised	Annualised
Diluted (in INR)	0.89	2.12	(1.67)	2.97
	0.89	2.12	(1.67)	2.97

See accompanying notes to the statement of unaudited consolidated financial results

Aster DM Healthcare Limited

CIN : L85110KA2008PLC147259

Registered office : No.1785, Sarjapur Road, Sector -1, HSR Layout, Ward No.174, Agara Extension, Bangalore-560102, Karnataka, India

Segment details of unaudited consolidated financial results for the quarter ended 30 June 2021

(Amount in INR crores)

Particulars	Quarter ended			Year ended
	30 June 2021 (Unaudited)	31 March 2021 (refer note 11)	30 June 2020 (Unaudited)	31 March 2021 (Audited)
1 Segment Revenue				
Hospitals	1,370.51	1,313.70	981.38	4,798.89
Clinics	561.94	586.45	350.22	2,014.46
Retail Pharmacies (including opticals)	436.46	488.26	412.92	1,783.12
Others	2.68	2.47	2.65	11.96
Total	2,371.59	2,390.88	1,747.17	8,608.43
2 Segment results before tax				
Hospitals	121.06	122.07	29.42	357.43
Clinics	57.92	89.49	(22.64)	152.16
Retail Pharmacies (including opticals)	24.10	40.00	25.89	148.69
Others	0.60	0.48	0.15	1.47
Total	203.68	252.04	32.82	659.75
Less :				
Finance cost	(66.46)	(76.73)	(80.28)	(293.66)
Exceptional items	-	-	-	-
Share of profit/ (loss) of equity accounted investees	1.04	0.45	1.02	3.52
Other unallocable expenditure net of unallocable income	(67.77)	(53.79)	(38.28)	(164.56)
(Loss)/ profit before tax	70.49	121.97	(84.72)	205.05
3 Segment Assets				
Hospitals	7,532.40	7,393.94	7,604.81	7,393.94
Clinics	1,793.50	1,805.63	1,897.16	1,805.63
Retail Pharmacies (including opticals)	1,459.96	1,361.74	1,633.41	1,361.74
Others	16.85	17.13	18.95	17.13
Unallocated	1,050.61	1,065.02	1,108.23	1,065.02
Total	11,853.32	11,643.46	12,262.56	11,643.46
4 Segment Liabilities				
Hospitals	3,752.26	3,720.80	3,630.12	3,720.80
Clinics	844.07	847.25	851.09	847.25
Retail Pharmacies (including opticals)	840.30	762.68	1,090.24	762.68
Unallocated	2,503.43	2,478.61	3,049.33	2,478.61
Total	7,940.06	7,809.34	8,620.78	7,809.34

See accompanying notes to the statement of unaudited consolidated financial results

Notes to the statement of unaudited consolidated financial results for the quarter ended 30 June 2021:

- The Statement of unaudited consolidated financial results ('the Statement') of Aster DM Healthcare Limited ('the Parent/ Company') and its subsidiaries (together referred to as 'the Group') and its share of profit in associates for the quarter ended 30 June 2021 has been reviewed by the Audit Committee and approved by the Board of Directors on 11 August 2021. The Statement has been subjected to limited review by Deloitte Haskins & Sells, the statutory auditor of the Company. The report of the statutory auditor is unmodified.
- During the quarter ended 31 March 2021 the Company has incurred net loss on fair valuation of put option liability amounting to INR 14.55 crore which is included under other expenses.
- During the quarter ended 30 June 2021, the Company has entered into share purchase agreement with Hindustan Drug House, a partnership firm registered under the Partnership Act, 1932. Hindustan Drug House is in the process of converting into a private limited company. The Company shall invest in 86% of the paid-up equity share capital of the converted private limited company.
- During the quarter ended 30 June 2021, the Nomination and Remuneration Committee of the Company approved the grant of 95,000 options (exercise price ranging from INR 10 to INR 118) to the employees of the Company and its subsidiaries under the Aster DM Healthcare Limited Employees Stock Option Plan 2013.
- In March 2020, the World Health Organisation declared COVID-19 to be a pandemic. This pandemic resulted in disruption to regular business operations due to lockdown, disruptions in transportation, travel bans, quarantines, social distancing and other emergency measures imposed by the government. The Group adopted measures to curb the spread of infection in order to protect the health of its employees and ensure business continuity with minimal disruption and has considered available internal and external information upto the date of approval of the financial results by the Board of Directors. The Group has used the principles of prudence in applying judgements, estimates and assumptions including sensitivity analysis and has evaluated impact of the pandemic in assessing the recoverability of property plant and equipment (including Capital work in progress), investments, intangibles, inventories, receivables and other assets based on its review of current indicators of future economic conditions. Based on current estimates, including the availability of financing facilities for maintaining liquidity, the Group expects to fully recover the carrying amount of these assets. Further, the Group has taken various measures to reduce its fixed cost - for example, salary reductions, optimization of administrative, sales and marketing costs, deferral of capex along with judicious resource allocation and requesting for the waiver of minimum guarantee fee and revenue share for hospital premises taken on lease. The eventual outcome of impact of the global health pandemic may be different from that which has been estimated as on the date of approval of these financial results. The Group will continue to monitor any material changes to future economic conditions and the consequent impact on its business, if any, and any significant impact of these changes would be recognized in the financial results as and when these material changes to economic conditions arise.

Aster DM Healthcare Limited

CIN : L85110KA2008PLC147259

Registered office : No.1785, Sarjapur Road, Sector -1, HSR Layout, Ward No.174, Agara Extension, Bangalore-560102, Karnataka, India

Notes to the statement of unaudited consolidated financial results for the quarter ended 30 June 2021 (continued):

- 6) The Indian Parliament has approved the Code on Social Security, 2020 and Code on Wages, 2019 ['Codes'] relating to employee benefits during employment and post-employment benefits in September 2020 and the same has received Presidential Assent. The Codes have been published in the Gazette of India. However, the date on which the Codes will come into effect has not yet been notified. The Company will need to assess the impact of the above. The impact will be recorded in the first period after the Codes become effective.
- 7) During the quarter ended 31 March 2021, the Company has reclassified rebates and discounts relating to pharmacy operations from revenue from operations to purchase of medicines and consumables. Comparative numbers for the quarter ended 30 June 2020 have been reclassified accordingly.

(Amount INR crores)

Particulars	Quarter ended 30 June 2020
Decrease in revenue from operations	13.46
Decrease in purchase of medicines and consumables	13.46

- 8) During the quarter ended 31 March 2021, the Company has adjusted the value of shares held by the ESOP Trust but not yet allotted to employees of INR 2.72 crores as at 31 March 2020 with the value of the issued, subscribed and paid up capital as at that date, which was previously included under other equity. Accordingly the previously reported financial results for the quarter ended 30 June 2020 have been restated as follows:

(Amount INR crores)

Particulars	As at 30 June 2020 (as previously stated)	As at 30 June 2020 (as restated)
Equity Share capital	499.52	496.80

- 9) During the quarter ended 31 March 2021, the Company reclassified certain other consumables from purchase of medicines and consumables to other expenses and has disclosed laboratory outsourcing charges as a separate item of expenditure previously included in other expenses. Comparative numbers for the quarter ended 30 June 2020 have been reclassified accordingly.

(Amount INR crores)

Particulars	Quarter ended 30 June 2020 (as previously stated)	Quarter ended 30 June 2020 (as restated)
Purchase of medicines and consumables*	633.22	631.66
Other Expenses	290.55	273.09
Laboratory outsourcing charges	-	19.02
Total expenses	923.77	923.77

* Purchase of medicines and consumables previously stated above is after factoring reclassification mentioned in note 7

- 10) The financial results of the Company for the quarter ended 30 June 2020, were reviewed by B S R & Associates LLP, Chartered Accountants, the predecessor auditor who have expressed an unmodified review conclusion.
- 11) The figures for the quarters ended 31 March 2021 is balancing figures between audited figures in respect of full financial years ended 31 March 2021 and the unaudited published year to date figures upto 31 December 2020, being the end of the third quarter of the respective financial year, which was subjected to Limited Review by the Statutory Auditors.
- 12) Statement of unaudited standalone financial results are available for perusal at the website of the Company and the stock exchanges.
- 13) Entities considered in preparation of statement of unaudited consolidated financial results are mentioned in Annexure A.

for and on behalf of the Board of Directors of

Aster DM Healthcare Limited

CIN : L85110KA2008PLC147259

MANDAYAPUR
ATH AZAD
MOOPEN

Digitally signed by
MANDAYAPURATH
AZAD MOOPEN
Date: 2021.08.11
19:37:02 +05'30'

Dr. Azad Moopen

Chairman and Managing Director

DIN 00159403

Dubai

11 August 2021

JAIDEEP
SATISHCHA
NDRA TRASI

Digitally signed
by JAIDEEP
SATISHCHANDRA
TRASI
Date: 2021.08.11
19:42:11 +05'30'

Aster DM Healthcare Limited

CIN : L85110KA2008PLC147259

Registered office : No.1785, Sarjapur Road, Sector -1, HSR Layout, Ward No.174, Agara Extension, Bangalore-560102, Karnataka, India

Annexure A to statement of unaudited consolidated financial results for the quarter ended 30 June 2021

SI No	Entity	Relationship	Country of incorporation
1	Aster DM Healthcare Limited	Parent	India
2	DM Med City Hospitals (India) Private Limited	Subsidiary	India
3	Ambady Infrastructure Private Limited	Subsidiary	India
4	Aster DM Healthcare (Trivandrum) Private Limited	Subsidiary	India
5	Malabar Institute of Medical Sciences Limited	Subsidiary	India
6	Prerana Hospital Limited	Subsidiary	India
7	Sri Sainatha Multispeciality Hospitals Private Limited	Subsidiary	India
8	Dr. Ramesh Cardiac and Multispeciality Hospitals Private Limited	Subsidiary	India
9	Aster Clinical Lab LLP	Subsidiary	India
10	Mindriot Research and Innovation Foundation	Subsidiary	India
11	Affinity Holdings Private Limited	Subsidiary	Mauritius
12	EMED Human Resources India Private Limited	Step down Subsidiary	India
13	Ezhimala Infrastructure LLP	Step down Subsidiary	India
14	Warseps Healthcare LLP	Step down Subsidiary	India
15	Sanghamitra Hospitals Private Limited	Step down Subsidiary	India
16	Aster Ramesh Duhita LLP	Step down Subsidiary	India
17	Komali Fertility Centre LLP (earlier Ramesh Fertility Centre LLP)	Step down Subsidiary	India
18	Aster Caribbean Holdings Limited	Step down Subsidiary	Cayman Island
19	Aster Cayman Hospital Limited	Step down Subsidiary	Cayman Island
20	Aster DM Healthcare FZC	Step down Subsidiary	UAE
21	Aster Hospital Sonapur L.L.C	Step down Subsidiary	UAE
22	Radiant Healthcare L.L.C	Step down Subsidiary	UAE
23	Aster Day Surgery Centre LLC	Step down Subsidiary	UAE
24	DM Healthcare (L L C)	Step down Subsidiary	UAE
25	Wahat Al Aman Home Health Care L.L.C.	Step down Subsidiary	UAE
26	Aster Grace Nursing and Physiotherapy LLC	Step down Subsidiary	UAE
27	Aster Pharmacies Group LLC	Step down Subsidiary	UAE
28	New Aster Pharmacy DMCC	Step down Subsidiary	UAE
29	Medshop Garden Pharmacy LLC	Step down Subsidiary	UAE
30	Aster DCC Pharmacy LLC	Step down Subsidiary	UAE
31	Aster Al Shafar Pharmacies Group LLC	Step down Subsidiary	UAE
32	Rafa Pharmacy LLC	Step down Subsidiary	UAE
33	Aster Pharmacy LLC, AUH	Step down Subsidiary	UAE
34	Med Shop Drugs Store LLC	Step down Subsidiary	UAE
35	Alfa Drug Store LLC	Step down Subsidiary	UAE
36	Alfa One Drug Store LLC	Step down Subsidiary	UAE
37	Alfaone FZ-LLC	Step down Subsidiary	UAE
38	DM Pharmacies LLC **	Step down Subsidiary	UAE
39	Aster Opticals LLC	Step down Subsidiary	UAE
40	Medcare Hospital (L.L.C)	Step down Subsidiary	UAE
41	Premium Healthcare Limited	Step down Subsidiary	UAE
42	Dr. Moopens Healthcare Management Services LLC	Step down Subsidiary	UAE
43	Eurohealth Systems FZ LLC	Step down Subsidiary	UAE
44	Al Rafa Investments Limited	Step down Subsidiary	UAE
45	Al Rafa Holdings Limited	Step down Subsidiary	UAE
46	Alfa Investments Limited #	Step down Subsidiary	UAE
47	Active Holdings Limited	Step down Subsidiary	UAE
48	Al Rafa Medical Centre LLC	Step down Subsidiary	UAE
49	Dar Al Shifa Medical Centre LLC	Step down Subsidiary	UAE
50	Aster Primary Care LLC	Step down Subsidiary	UAE
51	Modern Dar Al Shifa Pharmacy LLC	Step down Subsidiary	UAE
52	Harley Street LLC	Step down Subsidiary	UAE
53	Harley Street Pharmacy LLC	Step down Subsidiary	UAE
54	Harley Street Medical Centre LLC	Step down Subsidiary	UAE
55	Harley Street Dental LLC	Step down Subsidiary	UAE
56	Grand Optics LLC	Step down Subsidiary	UAE
57	Noor Al Shefa Clinic LLC	Step down Subsidiary	UAE

Aster DM Healthcare Limited

CIN : L85110KA2008PLC147259

Registered office : No.1785, Sarjapur Road, Sector -1, HSR Layout, Ward No.174, Agara Extension, Bangalore-560102, Karnataka, India

Annexure A to statement of unaudited consolidated financial results for the quarter ended 30 June 2021

SI No	Entity	Relationship	Country of incorporation
58	Zahrath Al Shefa Medical Center L.L.C	Step down Subsidiary	UAE
59	Zahrath Al Shefa Pharmacy LLC	Step down Subsidiary	UAE
60	Samary Pharmacy LLC	Step down Subsidiary	UAE
61	Metro Meds Pharmacy L.L.C	Step down Subsidiary	UAE
62	Metro Medical Center L.L.C	Step down Subsidiary	UAE
63	Symphony Healthcare Management Services LLC	Step down Subsidiary	UAE
64	E-Care International Medical Billing Services Co. LLC	Step down Subsidiary	UAE
65	Al Raffah Hospital LLC	Step down Subsidiary	Oman
66	Al Raffah Pharmacies Group LLC	Step down Subsidiary	Oman
67	Oman Al Khair Hospital L.L.C	Step down Subsidiary	Oman
68	Dr. Moopen's Healthcare Management Services WLL	Step down Subsidiary	Qatar
69	Welcare Polyclinic W.L.L	Step down Subsidiary	Qatar
70	Dr. Moopens Aster Hospital WLL	Step down Subsidiary	Qatar
71	Sanad Al Rahma for Medical Care LLC	Step down Subsidiary	Kingdom of Saudi Arabia
72	Aster DM Healthcare WLL (earlier Aster DM Healthcare SPC)	Step down Subsidiary	Bahrain
73	Orange Pharmacies LLC	Step down Subsidiary	Jordan
74	Al Shafar Pharmacy LLC, AUH **	Step down Subsidiary	UAE
75	Aster DM Healthcare INC **	Step down Subsidiary	Philippines
76	Aster Medical Centre LLC**	Step down Subsidiary	UAE
77	Aster Kuwait Pharmaceuticals and Medical Equipment Company W.L.L **	Step down Subsidiary	Kuwait
78	MIMS Infrastructure and Properties Private Limited	Associates	India
79	Alfaone Medicals Private Limited	Associates	India
80	Alfaone Retail Pharmacies Private Limited	Associates	India
81	Aries Holdings FZC	Associates	UAE
82	AAQ Healthcare Investments LLC	Associates	UAE
83	Aries Investments LLC	Associates	UAE
84	Al Mutamaizah Medicare Healthcare Investment Co. LLC	Associates	UAE

The principal place of business of all the entities listed above is the same as their respective countries of incorporation.

** represents subsidiaries which are in the process of being wound-up.